About: Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer
Creator	Chen, Chen, Baoan Chen, Jibei Chen, Runzhe Quek, Kelly Zhang, Hongming
source	Medline; PMC
abstract	Recent studies have revealed that cancer patients had a higher risk of having coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to patients without cancer. The expression of angiotensin-converting enzyme 2 (ACE2), the receptor of SARS-CoV-2, was aberrantly expressed in many tumors. In this study, by exploring the TCGA and GTEx public databases, we investigated ACE2 expression and its association with prognosis in non-small cell lung cancer (NSCLC), the most susceptible caner type. We found that lung was one of the major organs with highly expressed ACE2. Furthermore, ACE2 expression was significantly elevated in lung adenocarcioma (LUAD) and lung squamous cell carcinoma (LUSC) compared to normal tissues. DNA methylation might be one possible mechanism leading to ACE2 upregulation. Despite that, the AEC2 expression was not statistically associated with disease-free survival (DFS) and overall survival (OS) for LUAD patients, and higher ACE2 expression was associated with prolonged DFS in LUSC patients. Taken together, we observed ACE2 was highly expressed in LUAD and LUSC despite the controversial role of ACE2 expression in predicting prognosis in these two common lung cancer types.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.7150/jca.49462
bibo:pmid	32742475
has license	cc-by
sha1sum (hex)	2c9ed1a81409d9a2f8b1f098871ac9ce9efc308a
schema:url	https://doi.org/10.7150/jca.49462
resource representing a document's title	Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer
has PubMed Central identifier	PMC7391203
has PubMed identifier	32742475
schema:publication	J Cancer
resource representing a document's body	covid:2c9ed1a81409d9a2f8b1f098871ac9ce9efc308a#body_text
is schema:about of	named entity 'patients' named entity 'survival' named entity 'compared' named entity 'ACE2' named entity 'mechanism' named entity 'Recent' named entity 'investigated' named entity 'non-small cell lung cancer' named entity 'expression' named entity 'DNA methylation' named entity 'caner' named entity 'tissues' named entity 'study' named entity 'studies' named entity 'patients' named entity 'type' named entity 'types' named entity 'receptor' named entity 'tumors' named entity 'ACE2' named entity 'LUAD' named entity 'LUSC' named entity 'ACE2' named entity 'ACE2' named entity 'ACE2' named entity 'higher risk' named entity 'DNA methylation' named entity 'COVID' named entity 'expression' named entity 'ACE2' named entity 'lung cancer' named entity 'SARS-CoV-2' named entity 'non-small cell lung cancer' named entity 'LUAD' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'ACE2' named entity 'lung' named entity 'lung adenocarcinoma' named entity 'NSCLC' named entity 'lung cancer' named entity 'lung cancer' named entity 'LUSC' named entity 'inclination' named entity 'lung tumors' named entity 'ACE2' named entity 'LUSC' named entity 'SARS-CoV-2' named entity 'therapeutic strategies' named entity 'SARS-CoV-2' named entity 'TCGA' named entity 'ACE2' named entity 'virus' named entity 'ACE2' named entity 'lung tumors' named entity 'LUSC' named entity 'ACE2' named entity 'LUSC' named entity 'prognosis' named entity 'COVID' named entity 'COVID' named entity 'ACE2' named entity 'tumors' named entity '3, 4' named entity 'ACE2' named entity 'lung cancer' named entity 'LUSC' named entity 'tumor' named entity 'tumors' named entity 'ACE2' named entity 'ACE2' named entity 'DFS' named entity 'COVID-19 pandemic' named entity 'methylated' named entity 'LUAD' named entity 'Genotype' named entity 'lung cancer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software